Coya Therapeutics, Inc. · NASDAQ:COYA

Coya Therapeutics — Investor Presentation (February 2024)

37 slides from Coya Therapeutics's investor presentation, February 2024

  1. Slide 1: Unleashing the Power of Regulatory T cells (Tregs)

    Unleashing the Power of Regulatory T cells (Tregs) Investor Presentation February 2024 NASDAQ: COYA www.coyatherapeutics.com

  2. Slide 2: Cautionary Note of Forward-Looking Statements and Disclaimers

    Cautionary Note of Forward-Looking Statements and Disclaimers This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements incl

  3. Slide 3: Investment Highlights

    Investment Highlights • Clinically-advanced company focused on Regulatory T cell (Treg) therapies with strong Market Capitalization Table early clinical data Symbol NASDAQ: COYA ⎼ COYA 302 – Lead asset expected to initiate Ph. 2 in 1H24 in ALS (Lou Gehrig’s disease); also being explored in Parkinson

  4. Slide 4: Coya – Critical Milestones Over the Next 2 Years

    Coya – Critical Milestones Over the Next 2 Years 1H 2024 2H 2024 2025 • COYA 302 File IND and Initiate • COYA 301 Proof of Concept • COYA 302 Phase 2 Topline Data in Phase 2 Trial in ALS Patients combination data with Drug X in ALS Patients AD mice model • COYA 301 Presentation of • COYA 302 Phase 2

  5. Slide 5: COYA 302

    Neurodegenerative Diseases Involve Complex Pathophysiology Multi-modal Combination Therapies May be Transformative Journal of Neuroinflammation volume 19, Article number: 251 (2022 COYA 302 Proprietary Combination Biologic Lead Asset Like Oncology and Viral Disease, Combination Therapies May Be Tran

  6. Slide 6: Strong Proof-of-Concept Clinical Data

    Strong Proof-of-Concept Clinical Data COYA 302 COYA 302 for for the the Treatment Treatment of of COYA COYA301 301for for the the Treatment ofAlzheimer’s Treatment of Alzheimer’s Amyotrophic Lateral Amyotrophic Lateral Sclerosis* Sclerosis* Disease* disease* Open-label academic study in 4 ALS patien

  7. Slide 7: Coya's Leadership Has Demonstrated Deep Expertise in Biotech

    Coya’s Leadership Has Demonstrated Deep Expertise in Biotech Management Team Howard Berman, Ph.D. Fred Grossman, D.O., FAPA David Snyder Arun Swaminathan, Ph.D. Michelle Frazier Chief Executive Officer & President & Chief Medical Chief Financial Officer & Chief Business Development Officer Senior Vi

  8. Slide 8: SAB Comprised of Seminal Leadership in Tregs

    SAB Comprised of Seminal Leadership in Tregs Following the discoveries of Dr. Sakaguchi and Dr. Appel, Coya is developing multiple product modalities to enhance the therapeutic Shimon Sakaguchi, MD, PhD Stanley Appel, MD potential of Tregs for the Distinguished Professor at the World Premier Former

  9. Slide 9: COYA 302 Program

    COYA 302 Program Partnerships / Product Type Discovery Preclinical IND-Enabling Phase 1 Phase 2 Phase 3 2024 Milestones Collaborations 1H 2024: IND filing and Ph2 Licensing initiation COYA 302 COYA 302 (Low Dose IL-2 + CTLA4 Ig) Transaction Treg-Enhancing / on 12/6/23: 1H 2024: PoC Peer- T Effector

  10. Slide 10: Other Treg Enhancing Therapeutics

    Other Treg Enhancing Therapeutics Partnerships / Product Type Discovery Preclinical IND-Enabling Phase 1 Phase 2 Phase 3 Milestones Collaborations COYA 301 (Low Dose IL-2) Retained COYA 301 Summer 2024: Academic Worldwide Treg-Enhancing Biologic Alzheimer’s Disease (AD) Rights IIT double blind Ph2 d

  11. Slide 11: Inflammation Plays a Critical Role in Neurodegeneration

    Inflammation Plays a Critical Role in Neurodegeneration: Regulatory T cells (Tregs) Dysfunction Neurodegeneration: Loss of Selective Inflammation in the Nervous System Population of Neurons Healthy Neuron Sick Neuron Dead Neuron Tregs play central role in inflammation and progression of neurodegener

  12. Slide 12: What Are Tregs and How They Are Dysfunctional

    What Are Tregs and How They Are Dysfunctional Tregs are a type of lymphocyte that modulate the body’s immune response The main functions of Tregs are: • Ameliorate inflammatory Healthy Tregs Dysfunctional Tregs mechanisms and reactions Tregs are important anti-inflammatory immune When Tregs become d

  13. Slide 13: Tregs Regulate Multiple Downstream Pathways to Reduce Inflammation

    Tregs Regulate Multiple Downstream Pathways to Reduce Inflammation Adaptive Immune System Innate Immune System Romano et al., Frontiers in Neurology, 31 January 2019 doi: 10.3389/fimmu.2019.00043 13

  14. Slide 14: Adaptive Immune System Involvement in ALS: Treg Dysfunction

    Adaptive Immune System Involvement in ALS: Treg Dysfunction Is a Core Driver of Neurodegeneration Treg dysfunction is associated with ALS disease progression and …and is similarly associated in burden of disease… other neurodegenerative diseases Treg Dysfunction is Associated Treg Dysfunction Plays

  15. Slide 15: Multiple Immune Pathways Involved in Complex Neurodegenerative Diseases

    Multiple Immune Pathways Involved in Complex Neurodegenerative Diseases Macrophages Promote Dysfunction of Tregs Releasing Regulatory T Cell Proinflammatory Cytokines and Oxidative Stress IL-1β NO, O2- FoxP3 IL-18 4-HNE IL-6 H2O2 TNF Oxidative Stress/Cytokines contribute to pathophysiology of neuro

  16. Slide 16: COYA 302

    COYA 302 A Proprietary Dual Biologic Combination Therapy to Address the Complex Pathophysiology in Neurodegeneration 16

  17. Slide 17: COYA 302: Combination Immunotherapy Targeting Adaptive and Innate Immune System

    COYA 302: Combination Immunotherapy Targeting the Adaptive and Innate Immune System that Drives ALS Pathophysiology Dysfunctional Treg Proinflammatory Macrophages Adaptive and Innate Immune-Mediated Neuroinflammation CD80 CD80 Low Dose IL-2 + CTLA4 Ig = Low Dose IL-2 CTLA4 Ig FoxP3 FoxP3 FoxP3 FoxP3

  18. Slide 18: COYA 302: A Novel Approach to the Treatment of Neurodegenerative Diseases

    COYA 302: A Novel Approach to the Treatment of Neurodegenerative Diseases Unique combination compared to commercial IL-2 (High Dose Lyophilized Format) or CTLA4-Ig (Orencia) New Indications Ready-to- including ALS, Unique low dose Well-established administer stable Alzheimer's, strength and GMP subc

  19. Slide 19: Current Therapies for ALS Aim to Slow Disease Progression

    Current Therapies for ALS Aim to Slow Disease Progression Many companies have garnered significant value by demonstrating a limited benefit of slowing the rate of ALS progression PRO-ACT ALS Database RELYVRIO Clinical Data2 RADICAVA Clinical Data3 ALSFRS-R Mean Change at Week ALSFRS-R Mean Change at

  20. Slide 20: COYA 302: Open-Label, Single-Arm PoC Clinical Study in ALS Patients

    COYA 302: Open-Label, Single-Arm PoC Clinical Study in ALS Patients (N=4) Screening Treatment Period Follow-Up 20 weeks COYA 302 was administered via subcutaneous 8 weeks injection over 48 weeks Screening Assessments Treatment Period Assessments Post-Treatment Assessments ✓ Clinical Labs ✓ Safety an

  21. Slide 21: COYA 302: PoC Trial Patient Demographics and Baseline Characteristics

    COYA 302: PoC Trial Patient Demographics and Baseline Characteristics ALS Progression Age Prior to Baseline Respiratory (years) Sex Type Onset (ALSFRS-R score) Respiratory Status Support No Respiratory Patient 1 47 Female Familial Limb -1.6 points / month None Insufficiency Respiratory Non-invasive

  22. Slide 22: COYA 302: Appears to Ameliorate ALS Progression Over Weeks

    COYA 302: Appears to Ameliorate ALS Progression Over 48 Weeks Mean (±SD) ALSFRS-R Score (N=4) 48 44 33.5 32 30 33.75 40 36 ALSFRS-R Score 32 28 24 20 16 48-Week Treatment Follow-Up 12 n.s. 8 n.s. 4 0 (Weeks) B 4 8 12 16 20 24 28 32 36 40 44 48 52 56 COYA 302 was well tolerated over 48 weeks; the mos

  23. Slide 23: COYA 302: Enhanced Biologic Activity

    COYA 302: Enhanced Biologic Activity Mean (SD) Treg Suppressive Function (N=4) Mean (SD) Percentage of CD4+CD25+FoxP3+ Treg Cells (N=4) CD4+CD25+FoxP3+ Treg Cells (%) 100 Treg Suppressive Function (%) 90 ** ** ** 12 Key Takeaways 80 * 10 70 * 8 60 50 6 ✓ COYA 302 significantly expands Treg 40 suppre

  24. Slide 24: COYA 302: Overview of Phase 2 Study Design in ALS

    COYA 302: Overview of Phase 2 Study Design in ALS Primary Endpoint Key Inclusion Criteria Randomized, Double-Blind, Placebo- Controlled Phase 2 with Open-Label Extension • Diagnosis of sporadic or familial Combined Assessment ALS 4 wk. 24 wk. Double Blind 4 wk. Safety 24 wk. Open-Label of Function (

  25. Slide 25: COYA 301

    COYA 301 A Proprietary Low-Dose IL-2 to Address Neurodegenerative Diseases as Monotherapy and as a Platform to Add Novel Synergistic Biologic Agents 25

  26. Slide 26: COYA 301: Proprietary Treg Enhancing Low-Dose IL-2

    COYA 301: Proprietary Treg Enhancing Low-Dose IL-2 Suppresses Adaptive Immunity Robustly and Innate Immunity Modestly Treg Expansion/Suppressive Function Dysfunctional Tregs COYA 301 are associated with neuroinflammation promoted by activated ALS Dysfunctional Treg Functional Tregs T effector cells

  27. Slide 27: COYA 301: Investigator-Initiated Study in Alzheimer's Disease

    COYA 301: Investigator-Initiated Study in Alzheimer’s Disease (AD) Overall Study Design • Proof-of-Concept open-label study, conducted at Houston Methodist Hospital • Population: 8 patients with mild-to-moderate AD • Treatment: 4 monthly COYA 301 cycles administered subcutaneously, followed by 2-mon

  28. Slide 28: COYA 301: Improved or Halted Cognitive Decline in AD Patients

    COYA 301: Improved or Halted Cognitive Decline in AD Patients MMSE Score (N=8) CDR-SB Score (N=8) ADAS-Cog Score (N=8) Treatment F/U 60 8 28 ns ns ** * * 50 * 24 6 Mean (SD) Score 40 Mean (SD) Score Mean (SD) Score 20 30 4 16 20 2 12 10 0 8 0 0 120 168 0 30 60 90 120 168 0 120 168 Study Day Study Da

  29. Slide 29: COYA 301: Enhanced Treg Function and Numbers in vivo in AD Patients

    COYA 301: Enhanced Treg Function and Numbers in vivo in AD Patients (N=8) Statistically Significant Enhancement Statistically Significant Enhancement of Treg Suppressive Function of Treg Numbers Treatment F/U Treatment F/U 14 * *** * * Mean (SD) Percentage of Tregs (% of CD4) * ** *** *** 100 12 Mea

  30. Slide 30: COYA 301: Significantly Lowered Plasma Proinflammatory Chemokines and Cytokines

    COYA 301: Significantly Lowered Plasma Proinflammatory Chemokines and Cytokines in AD Patients CCL11 Plasma Levels (N=8) CCL2 Plasma Levels (N=8) IL-15 Plasma Levels (N=8) Treatment F/U 600 Treatment F/U 500 Treatment F/U 14 550 ** ** * *** *** * ** *** ** ** * ** 450 12 Mean (SD) Level (pg/mL) Mean

  31. Slide 31: COYA 301: Significantly Lowers Expression of Proinflammatory Cytokines

    COYA 301: Significantly Lowers Expression of Proinflammatory Cytokines in AD Patients TNFα Monocyte Expression IL-6 Monocyte Expression IL-1β Monocyte Expression Percent Change from Baseline (N=5) Mean Change from Baseline (N=5) Mean Change from Baseline (N=5) Study Day Study Day Study Day 8 30 38 6

  32. Slide 32: Case Study of Brain Imaging of AD Patient before and after COYA 301 treatment

    Case Study of Brain Imaging of AD Patient before and after COYA 301 treatment Mini-Mental State Examination (MMSE) Neuroinflammation (TSPO) 70-Year-Old Male 18 17 (11C) ER-176 PET Scan at Better 16 Baseline MMSE: 12 16 15 baseline and after 4-monthly 15 Positive PIB PET Scan 14 cycles of low dose IL

  33. Slide 33: COYA 301: Safety & Tolerability

    COYA 301: Safety & Tolerability • Overall, COYA 301 was well tolerated in patients with AD • Most common adverse events (AEs) were mild injection site reactions and mild leukopenia • All patients completed the study • No deaths or other serious AE occurred over the course of the study 33

  34. Slide 34: COYA 301: Double-Blind, Placebo-Controlled Study in AD Patients is Ongoing

    COYA 301: Double-Blind, Placebo-Controlled Study in AD Patients is Ongoing The encouraging results of the open-label, proof-of-concept study in AD (N=8) supported conducting the ongoing randomized, double-blind, well-controlled phase 2 study in 38 patients with mild-to-moderate AD. Low Dose IL-2– Do

  35. Slide 35: COYA 301: A Backbone for Combination Immunotherapy

    COYA 301: A Backbone for Combination Immunotherapy Activated T effector Cells Activated Macrophages/Microglia Treg Function and numbers CTLA4 Ig COYA Shown therapeutic benefit in ALS 302 patients COYA 301 Subcutaneous + Beta Amyloid Inhibitors COYA 303* Alzheimer’s Disease Low-Dose Interleukin-2 Fer

  36. Slide 36: Coya – Critical Milestones Over the Next 2 Years

    Coya – Critical Milestones Over the Next 2 Years 1H 2024 2H 2024 2025 • COYA 302 File IND and Initiate • COYA 301 Proof of Concept • COYA 302 Phase 2 Topline Data in Phase 2 Trial in ALS Patients combination data with Drug X in ALS Patients AD mice model • COYA 301 Presentation of • COYA 302 Phase 2

  37. Slide 37: NASDAQ: COYA

    Investor Contact: David Snyder david@coyatherapeutics.com CORE IR Media Contact: Bret Shapiro Jessica Starman brets@coreir.com media@coyatherapeutics.com 561-479-8566 NASDAQ: COYA 888-461-2233

Coya Therapeutics — Investor Presentation (February 2024) on 6ix